

## Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2018 ending March 2019

Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today that it has revised the consolidated financial forecast for the fiscal 2018 that was disclosed on May 11, 2018 as follows based on results of operations thus far in the fiscal year.

### 1. Revision of consolidated financial forecasts for the fiscal 2018

(April 1, 2018 to March 31, 2019)

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share (Yen)
Previous Forecast (A)	28,100	400	2,250	1,700	30.11
Revised Forecast (B)	28,350	950	2,800	2,200	38.97
Change (B - A)	250	550	550	500	—
Change (%)	0.9	137.5	24.4	29.4	—
Reference: Results for fiscal 2017	30,175	1,421	5,327	3,922	69.30

### 2. Reason for the revision

Net sales are projected to slightly exceed the previous forecast due to the positive impact of exchange rates accompanying yen depreciation and sales increases from the LAL business and bulk products. This result comes despite a greater-than-expected decline in sales of domestic pharmaceuticals. With regard to earnings, although R&D expenses are projected to be slightly higher than previous forecast, operating income, ordinary income, and net income attributable to owners of parent are expected to exceed the previous forecasts due to a decrease in selling, general and administrative expenses because of cost-cutting measures and other factors.

Seikagaku projects R&D expenses of ¥7,150 million (¥100 million above the previous forecast of ¥7,050 million).

#### <Cautionary Notes>

This press release contains forward-looking statements regarding future management strategies or performance forecasts. These descriptions are based on judgments derived from information that is currently available to Seikagaku and are subject to risk and uncertainty. Actual results and developments may differ significantly from these descriptions due to various factors.

Information about pharmaceutical products or medical devices (including products currently in development) contained in this press release is not intended to constitute an advertisement or medical advice.